EODData

MEMBERSHIP REGISTER LOG IN

BRU, UCB: UCB SA

03 Oct 2025
LAST:

252.0

CHANGE:
 5.60		OPEN:
246.0		HIGH:
253.6		ASK:
66.0		VOLUME:
205.1K
CHG(%):
2.27		PREV:
246.4		LOW:
245.6		BID:
64.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Oct 25246.0253.6245.6252.0205.1K
02 Oct 25247.1251.2244.6246.4248K
01 Oct 25244.3247.2242.4245.7383.8K
30 Sep 25225.9237.2222.5235.0319.1K
29 Sep 25230.0237.0226.5227.6976.3K
26 Sep 25192.6200.3191.2196.9204.4K
25 Sep 25203.4203.6196.5196.5271.9K
24 Sep 25204.3206.0202.3204.5131.2K
23 Sep 25205.6206.3203.2204.497.2K
22 Sep 25204.3207.6203.0206.5118.5K

COMPANY PROFILE

Name:UCB SA
About:UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Sector:Healthcare
Industry:Biotechnology
Address:Allée de la Recherche, 60, Brussels, Belgium, 1070
Website:https://www.ucb.com
ISIN:BE0003739530
LEI:2138008J191VLSGY5A09

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:14.85
EPS Ratio:2.20
DivYield:0.01
Div/Share:1.39
Price to Book:1.13
Price to Sales:5.52
EBITDA:1.852B
Shares:121.47M
Market Cap:30.611B

TECHNICAL INDICATORS

MA5:241.34
MA10:221.55
MA20:213.99
MA50:201.41
MA100:184.23
MA200:175.95
STO9:97.28
STO14:97.28
RSI14:82.25
MTM14:48.10
ROC14:0.24
ATR:8.67
Week High:253.55
Week Low:191.20
Month High:253.55
Month Low:191.20
Year High:253.55
Year Low:129.35
Volatility:4.11

RECENT SPLITS

Date Ratio
04 Jan 1999100-1

RECENT DIVIDENDS

Date Amount
25 Apr 2025$0.97
26 Apr 2024$0.95
28 Apr 2023$0.93
29 Apr 2022$0.91
30 Apr 2021$0.89
04 May 2020$0.87
26 Apr 2019$0.85
27 Apr 2018$0.83
28 Apr 2017$0.81
29 Apr 2016$0.80